New Markers for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2011 Apr 14

PMID 21487112

Citations 131

Authors

Elaine Coustan-Smith

Guangchun Song

Christopher Clark

Laura Key

Peixin Liu

Mohammad Mehrpooya

Patricia Stow

Xiaoping Su

Sheila Shurtleff

Ching-Hon Pui

James R Downing

Dario Campana

Affiliations

Soon will be listed here.

Abstract

To identify new markers for minimal residual disease (MRD) detection in acute lymphoblastic leukemia (ALL), we compared genome-wide gene expression of lymphoblasts from 270 patients with newly diagnosed childhood ALL to that of normal CD19⁺CD10⁺ B-cell progenitors (n = 4). Expression of 30 genes differentially expressed by ≥ 3-fold in at least 25% of cases of ALL (or 40% of ALL subtypes) was tested by flow cytometry in 200 B-lineage ALL and 61 nonleukemic BM samples, including samples containing hematogones. Of the 30 markers, 22 (CD44, BCL2, HSPB1, CD73, CD24, CD123, CD72, CD86, CD200, CD79b, CD164, CD304, CD97, CD102, CD99, CD300a, CD130, PBX1, CTNNA1, ITGB7, CD69, CD49f) were differentially expressed in up to 81.4% of ALL cases; expression of some markers was associated with the presence of genetic abnormalities. Results of MRD detection by flow cytometry with these markers correlated well with those of molecular testing (52 follow-up samples from 18 patients); sequential studies during treatment and diagnosis-relapse comparisons documented their stability. When incorporated in 6-marker combinations, the new markers afforded the detection of 1 leukemic cell among 10(5) BM cells. These new markers should allow MRD studies in all B-lineage ALL patients, and substantially improve their sensitivity.

Citing Articles

Analysis of Antigen Expression in T-Cell Acute Lymphoblastic Leukemia by Multicolor Flow Cytometry: Implications for the Detection of Measurable Residual Disease.

Semchenkova A, Mikhailova E, Demina I, Roumiantseva J, Karachunskiy A, Novichkova G Int J Mol Sci. 2025; 26(5).

PMID: 40076625 PMC: 11899820. DOI: 10.3390/ijms26052002.

The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.

Stajer M, Horacek J, Kupsa T, Zak P J Appl Biomed. 2025; 22(4):165-184.

PMID: 40033805 DOI: 10.32725/jab.2024.024.

CD38 and CD58: A Gallant Savior in Under-Resourced Laboratories.

Agarwal A, Rana D, More S, Sikka M, Dewan P, Kotru M Cureus. 2024; 16(11):e72968.

PMID: 39634988 PMC: 11615999. DOI: 10.7759/cureus.72968.

Immunophenotypic Characteristics and Cytogenetic Analysis of Adolescent and Young Adult B-Cell Acute Lymphoblastic Leukemia: Correlations With Clinicopathological Parameters.

Yadav V, Raveendranath V, Ganesan P, Kar R, R P, Manivannan P Cureus. 2024; 16(9):e68735.

PMID: 39371707 PMC: 11454831. DOI: 10.7759/cureus.68735.

The significance of CD49f expression in pediatric B-cell acute lymphoblastic leukemia.

Hunyadi A, Kriston C, Szaloki G, Peterffy B, Egyed B, Szepesi A Am J Clin Pathol. 2024; 163(2):169-177.

PMID: 39259664 PMC: 11821268. DOI: 10.1093/ajcp/aqae105.

References

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

Ferrando A, Armstrong S, Neuberg D, Sallan S, Silverman L, Korsmeyer S . Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003; 102(1):262-8. DOI: 10.1182/blood-2002-10-3221. View

Conter V, Bartram C, Valsecchi M, Schrauder A, Panzer-Grumayer R, Moricke A . Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010; 115(16):3206-14. DOI: 10.1182/blood-2009-10-248146. View

Cave H, van der Werff Ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med. 1998; 339(9):591-8. DOI: 10.1056/NEJM199808273390904. View

Mullighan C, Goorha S, Radtke I, Miller C, Coustan-Smith E, Dalton J . Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446(7137):758-64. DOI: 10.1038/nature05690. View

Krampera M, Vitale A, Vincenzi C, Perbellini O, Guarini A, Annino L . Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br J Haematol. 2002; 120(1):74-9. DOI: 10.1046/j.1365-2141.2003.03974.x. View

Kamps M, Look A, Baltimore D . The human t(1;19) translocation in pre-B ALL produces multiple nuclear E2A-Pbx1 fusion proteins with differing transforming potentials. Genes Dev. 1991; 5(3):358-68. DOI: 10.1101/gad.5.3.358. View

Tamura H, Dan K, Tamada K, Nakamura K, Shioi Y, Hyodo H . Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res. 2005; 11(16):5708-17. DOI: 10.1158/1078-0432.CCR-04-2672. View

Zhou J, Goldwasser M, Li A, Dahlberg S, Neuberg D, Wang H . Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007; 110(5):1607-11. PMC: 1975844. DOI: 10.1182/blood-2006-09-045369. View

10.

Raff T, Gokbuget N, Luschen S, Reutzel R, Ritgen M, Irmer S . Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2006; 109(3):910-5. DOI: 10.1182/blood-2006-07-037093. View

11.

Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G . Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia. 2004; 19(1):49-56. DOI: 10.1038/sj.leu.2403559. View

12.

Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C . Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia. 2008; 22(12):2193-200. DOI: 10.1038/leu.2008.227. View

13.

Schepers H, Geugien M, van der Toorn M, Bryantsev A, Kampinga H, Eggen B . HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun. Exp Hematol. 2005; 33(6):660-70. DOI: 10.1016/j.exphem.2005.03.009. View

14.

Campana D . Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009; 23(5):1083-98, vii. PMC: 2762949. DOI: 10.1016/j.hoc.2009.07.010. View

15.

Coustan-Smith E, Behm F, Sanchez J, Boyett J, Hancock M, Raimondi S . Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998; 351(9102):550-4. DOI: 10.1016/S0140-6736(97)10295-1. View

16.

Lankester A, Bierings M, van Wering E, Wijkhuijs A, de Weger R, Wijnen J . Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia. 2010; 24(8):1462-9. DOI: 10.1038/leu.2010.133. View

17.

Coustan-Smith E, Sancho J, Behm F, Hancock M, Razzouk B, Ribeiro R . Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002; 100(1):52-8. DOI: 10.1182/blood-2002-01-0006. View

18.

Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B . Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol. 2008; 142(2):227-37. DOI: 10.1111/j.1365-2141.2008.07185.x. View

19.

Faderl S, OBrien S, Pui C, Stock W, Wetzler M, Hoelzer D . Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010; 116(5):1165-76. PMC: 5345568. DOI: 10.1002/cncr.24862. View

20.

Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E . CD200 is a new prognostic factor in multiple myeloma. Blood. 2006; 108(13):4194-7. DOI: 10.1182/blood-2006-06-029355. View